EyePoint and Rallybio shake hands on collaboration; Shionogi expects billions for Covid antiviral pill — report
EyePoint Pharmaceuticals and Rallybio will be entering into a partnership.
The deal will look at the delivery of Rallybio’s C5 inhibitor using EyePoint’s tech for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
